Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Accounts Payables: 2017-2025

Historic Accounts Payables for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $9.2 million.

  • Aclaris Therapeutics' Accounts Payables rose 19.90% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year increase of 19.90%. This contributed to the annual value of $4.7 million for FY2024, which is 47.17% down from last year.
  • Per Aclaris Therapeutics' latest filing, its Accounts Payables stood at $9.2 million for Q3 2025, which was up 4.43% from $8.8 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Accounts Payables high stood at $11.4 million for Q2 2023, and its period low was $4.2 million during Q2 2021.
  • For the 3-year period, Aclaris Therapeutics' Accounts Payables averaged around $8.4 million, with its median value being $8.8 million (2025).
  • As far as peak fluctuations go, Aclaris Therapeutics' Accounts Payables surged by 100.33% in 2023, and later slumped by 47.17% in 2024.
  • Aclaris Therapeutics' Accounts Payables (Quarterly) stood at $10.0 million in 2021, then increased by 3.67% to $10.4 million in 2022, then declined by 14.23% to $8.9 million in 2023, then slumped by 47.17% to $4.7 million in 2024, then increased by 19.90% to $9.2 million in 2025.
  • Its Accounts Payables stands at $9.2 million for Q3 2025, versus $8.8 million for Q2 2025 and $6.4 million for Q1 2025.